Caracterização de nanopartículas contendo insulina em modelos de animais induzidos ao diabetes / Characterization of nanoparticles containing insulin in animal models induced diabetes

AUTOR(ES)
FONTE

IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia

DATA DE PUBLICAÇÃO

05/08/2010

RESUMO

Diabetes Mellitus is a disease whose cases have increased due to the bad habits of life of society. Several strategies have been developed for the treatment of diabetes, especially the controlled release of drugs. The erroneous use of insulin as basal treatment of diabetes takes a problem, since the high dose of the drug can lead to severe hypoglycemia. The use of drug encapsulation by biocompatible and biodegradable polymers has been a good strategy for the controlled release of drugs, allowing the agent to be released on a continuous and sustained. In this context, the production and characterization of nanoparticles containing insulin are presented as a strategy of controlled release of this hormone. Thus, this project consisted of the preparation and characterization of biodegradable nanoparticles of poly (e-caprolactone) (PCL) as a carrier of insulin and its application in vivo and in vitro. The nanoparticles were prepared by the method of double emulsion w / o / a and solvent evaporation. The characterization of nanoparticles was performed by Scanning Electron Microscope (SEM), observing and spherical nanoparticles with different sizes. The encapsulation efficiency was 90.6% (± 1.6), analyzed by High Performance Liquid Chromatography (HPLC) via indirect. The average diameter of nanoparticles was 796 nm (PDI = 0.49) and zeta potential as measured by photon correlation spectroscopy (PCS) of -29.4 ± 2.7 mV. The cell viability was performed in tumoral pancreatic (3 cells (6 min) at different concentrations and times using the MTS. A decrease in cell viability only at 72 at all concentrations. The evaluation of sustained release of drug was performed by in vivo studies with male Wistar rats with type 1 diabetes, results confirmed that the nanoparticles containing insulin present continuous and sustained release as compared to non-encapsulated insulin. Furthermore, we found that treatment with nanoparticles containing insulin did not cause liver toxicity by evaluating cell death (caspase 3 cleavage), and oxidative stress (catalase, superoxide dismutase and peroxiredoxins). The use of insulin nanoencapsulated pharmacokinetic advantages over the use of insulin free, and no reported hepatotoxicity. Thus, our results add important values in the clinical treatment of type 1 diabetes, leading to a promising future in the use of these polymeric nanoparticles containing insulin.

ASSUNTO(S)

nanopartículas insulina diabetes nanoparticles insulin diabetes

ACESSO AO ARTIGO

Documentos Relacionados